Three Firms Aim To Launch Therapies For Hereditary Angioedema In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Lev, which submitted a BLA in July, is vying with Dyax and German firm Jerini to launch drugs next year.
You may also be interested in...
Jerini Submits Icatibant NDA; Asks FDA For Priority Review
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
Jerini Submits Icatibant NDA; Asks FDA For Priority Review
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
Jerini’s Icatibant Could Be Second To Market For Hereditary Angioedema
Jerini submits NDA for bradykinin blocker just over two months after Lev Pharmaceuticals’ Cinryze was filed.